IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 34, 2015, Pages 10762-10767

  Monticelli, Laurel A ^a   Osborne, Lisa C ^a   Noti, Mario ^b   Tran, Sara V ^a   Zaiss, Dietmar M W ^c   Artis, David ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Inflammatory bowel disease; Innate immunity; Innate lymphoid cell; Interleukin 33

Indexed keywords

AMPHIREGULIN; CD4 ANTIGEN; CLAUDIN 1; DEXTRAN SULFATE; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 5; MESSENGER RNA; MUCIN; MUCIN 2; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR GATA 3; AREG PROTEIN, MOUSE; EGFR PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR DERIVATIVE; IL33 PROTEIN, MOUSE; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; ENTERITIS; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTESTINE INJURY; INTESTINE LYMPHATIC TISSUE; LYMPHOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SINGLE CELL ANALYSIS; T LYMPHOCYTE; WEIGHT REDUCTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; CLASSIFICATION; COLITIS; DEFICIENCY; DISEASE MODEL; EPITHELIUM; FEEDBACK SYSTEM; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; INTESTINE MUCOSA; KNOCKOUT MOUSE; LUNG; LYMPHOCYTE; METABOLISM; MUCOSAL IMMUNITY; PATHOLOGY; PEYER PATCH; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; EGF FAMILY OF PROTEINS; EPITHELIUM; FEEDBACK, PHYSIOLOGICAL; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-33; INTESTINAL MUCOSA; LUNG; LYMPHOCYTES; MICE; MICE, KNOCKOUT; MUCINS; PEYER'S PATCHES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84940527399     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1509070112     Document Type: Article

References (40)

1. Rescigno M (2011) The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol 32(6):256-264.
2. Maloy KJ, Powrie F (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474(7351):298-306.
3. Peterson LW, Artis D (2014) Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nat Rev Immunol 14(3):141-153.
4. Crosby LM, Waters CM (2010) Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 298(6):L715-L731.
5. Kaser A, Zeissig S, Blumberg RS (2010) Inflammatory bowel disease. Annu Rev Immunol 28:573-621.
6. Ziegler SF, Artis D (2010) Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol 11(4):289-293.
7. Monticelli LA, et al. (2011) Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 12(11):1045-1054.
8. Zaiss DM, et al. (2006) Amphiregulin, a TH2 cytokine enhancing resistance to nematodes. Science 314(5806):1746.
9. Burzyn D, et al. (2013) A special population of regulatory T cells potentiates muscle repair. Cell 155(6):1282-1295.
10. Lopetuso LR, Scaldaferri F, Pizarro TT (2012) Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair 5(1):18.
11. García-Miguel M, González MJ, Quera R, Hermoso MA (2013) Innate immunity modulation by the IL-33/ST2 system in intestinal mucosa. BioMed Res Int 2013:142492.
12. Kobori A, et al. (2010) Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 45(10):999-1007.
13. Pastorelli L, et al. (2010) Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 107(17):8017-8022.
14. Sipos F, Molnár B, Zágoni T, Berczi L, Tulassay Z (2005) Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: Ulcerative colitis shows specific p53- and EGFR expression alterations. Dis Colon Rectum 48(4):775-786.
15. Sipos F, et al. (2010) Regeneration associated growth factor receptor and epithelial marker expression in lymphoid aggregates of ulcerative colitis. Scand J Gastroenterol 45(4):440-448.
16. Yan F, et al. (2011) Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 121(6):2242-2253.
17. Brandl K, et al. (2010) MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci USA 107(46):19967-19972.
18. Bartemes KR, et al. (2012) IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 188(3):1503-1513.
19. Barlow JL, et al. (2012) Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol 129(1):191-198.
20. Halim TY, Krauss RH, Sun AC, Takei F (2012) Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36(3):451-463.
21. Chang YJ, et al. (2011) Innate lymphoid cells mediate influenza-induced airway hyperreactivity independently of adaptive immunity. Nat Immunol 12(7):631-638.
22. Kim BS, et al. (2013) TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 5(170):170ra16.
23. Roediger B, et al. (2013) Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol 14(6):564-573.
24. Salimi M, et al. (2013) A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 210(13):2939-2950.
25. Neill DR, et al. (2010) Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464(7293):1367-1370.
26. Price AE, et al. (2010) Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA 107(25):11489-11494.
27. Moro K, et al. (2010) Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463(7280):540-544.
28. Camelo A, et al. (2012) Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol 47(11):1198-1211.
29. Perše M, Cerar A (2012) Dextran sodium sulphate colitis mouse model: Traps and tricks. J Biomed Biotechnol 2012:718617.
30. + regulatory T-cell responses in mice. Mol Med 18:753-761.
31. Grobeta P, Doser K, Falk W, Obermeier F, Hofmann C (2012) IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis 18(10):1900-1909.
32. Du X, et al. (2004) Velvet, a dominant Egfr mutation that causes wavy hair and defective eyelid development in mice. Genetics 166(1):331-340.
33. Zaiss DM, et al. (2013) Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 38(2):275-284.
34. Le H, Kim W, Kim J, Cho HR, Kwon B (2013) Interleukin-33: A mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies. Front Immunol 4:104.
35. Krishnan K, Arnone B, Buchman A (2011) Intestinal growth factors: Potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm Bowel Dis 17(1):410-422.
36. Schiering C, et al. (2014) The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513(7519):564-568.
37. Pastorelli L, De Salvo C, Cominelli MA, Vecchi M, Pizarro TT (2011) Novel cytokine signaling pathways in inflammatory bowel disease: Insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap Adv Gastroenterol 4(5):311-323.
38. Sedhom MA, et al. (2013) Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62(12):1714-1723.
39. Imaeda H, et al. (2011) Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis. Int J Mol Med 28(4):573-578.
40. Manzo ND, Foster WM, Stripp BR (2012) Amphiregulin-dependent mucous cell metaplasia in a model of nonallergic lung injury. Am J Respir Cell Mol Biol 47(3):349-357.